Your browser doesn't support javascript.
loading
A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
Seneschal, J; Lacour, J-P; Bewley, A; Faurby, M; Paul, C; Pellacani, G; De Simone, C; Horne, L; Sohrt, A; Augustin, M; Hammond, E; Reich, K.
Afiliación
  • Seneschal J; Department of Dermatology and Paediatric Dermatology, National Reference Centre for Rare Skin Diseases, Saint-André Hospital, University of Bordeaux, Bordeaux, France.
  • Lacour JP; Department of Dermatology, Archet 2 Hospital, University Hospital of Nice, Nice, France.
  • Bewley A; Department of Dermatology, Barts Health NHS Trust London, London, UK.
  • Faurby M; LEO Pharma A/S, Ballerup, Denmark.
  • Paul C; Toulouse University and Larrey Hospital, Toulouse, France.
  • Pellacani G; Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
  • De Simone C; Department of Dermatology, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Rome, Italy.
  • Horne L; AstraZeneca, Gaithersburg, MD, USA.
  • Sohrt A; LEO Pharma A/S, Ballerup, Denmark.
  • Augustin M; Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Centre Hamburg-Eppendorf (UKE), Hamburg, Germany.
  • Hammond E; AstraZeneca, Gaithersburg, MD, USA.
  • Reich K; Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation® Center, Hamburg, Germany.
J Eur Acad Dermatol Venereol ; 34(11): 2566-2573, 2020 Nov.
Article en En | MEDLINE | ID: mdl-32364296
ABSTRACT

BACKGROUND:

Anti-tumour necrosis factor (TNF) and anti-interleukin (IL)-12/23 biologics revolutionized plaque psoriasis treatment by enabling ≥75% improvement in the Psoriasis Area and Severity Index (PASI 75) in clinical trials. Modern biologics are now reported to achieve PASI 100 (complete skin clearance) in clinical trials. However, real-world evidence of skin clearance rates with biologics is limited. PSO-BIO-REAL was conducted to understand the real-world burden of plaque psoriasis.

OBJECTIVE:

The primary objective of this observational study was to estimate the proportion of patients who achieved complete skin clearance at 6 months. Secondary objectives included maintenance of response and evaluation of complete skin clearance at 12 months.

METHODS:

PSO-BIO-REAL was a multinational, prospective, real-world, non-interventional study of skin clearance and patient-reported outcomes (PROs) with biologics. A total of 846 patients from the United States (32%), France (28%), Italy (22%), the United Kingdom (11%) and Germany (8%) were enrolled and followed for one year. Eligible patients were aged ≥18 years with moderate-to-severe plaque psoriasis who had initiated a biologic for plaque psoriasis. Patients could be biologic-naïve or switching biologics (biologic-experienced). Assessments were made at baseline and at months 6 and 12.

RESULTS:

At 6 and 12 months, 23% and 26% of patients achieved complete skin clearance, respectively. Prior to study entry, 60% were biologic-naïve. The proportion of patients achieving complete skin clearance was lower among biologic-experienced patients (20% at both months 6 and 12) compared with biologic-naïve patients (25% at month 6, 30% at month 12). The rate of complete skin clearance decreased as the number of prior biologics and baseline comorbidities increased.

CONCLUSION:

Only one in four patients achieved complete skin clearance after 6 months of treatment with biologics. The study indicates there still is an unmet need for more efficacious biologics for patients with psoriasis.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Psoriasis / Productos Biológicos Tipo de estudio: Observational_studies Límite: Adolescent / Adult / Humans País/Región como asunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2020 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Psoriasis / Productos Biológicos Tipo de estudio: Observational_studies Límite: Adolescent / Adult / Humans País/Región como asunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2020 Tipo del documento: Article País de afiliación: Francia